Revumenib (SNDX-5613)
Menin Inhibitor
Phase 1
Phase 2
Pivotal
Registration
Indication(s)
BEAT-AML
(venetoclax/azacitidine combo)
Frontline KMT2Ar and NPM1m AML
INTERCEPT
(monotherapy)
MRD- progression in KMT2Ar and NPM1m AML
Colorectal Cancer
(monotherapy)
Unresectable metastaticmicrosatellite stable CRC
Axatilimab (SNDX-6352)
Anti-CSF-1R mAB
Phase 1
Phase 2
Pivotal
Registration
Indication(s)
Entinostat (SNDX-275)
Class 1 HDAC Inhibitor
Phase 1
Phase 2
Pivotal
Registration
Indication(s)
Revumenib (SNDX-5613)
Menin Inhibitor
BEAT-AML
Frontline KMT2Ar and NPM1m AML
Phase 1
INTERCEPT
MRD- progression in KMT2Ar and NPM1m AML
Phase 1
Colorectal Cancer
Unresectable metastatic microsatellite stable CRC
Phase 1
Axatilimab (SNDX-6352)
Anti-CSF-1R mAB
Entinostat (SNDX-275)
Class 1 HDAC Inhibitor
*Submission of registrational filing expected by year-end 2023